Owing to the risk of fetal loss associated with prenatal diagnostic procedures (amniocentesis, chorionic villus sampling), noninvasive prenatal diagnosis (NIPD) is ultimate goal of prenatal diagnosis. The discovery of circulating cell-free fetal DNA (cffDNA) in maternal plasma in 1997 has opened up new probabilities for NIPD by Dr. Lo et al. The last decade has seen great development in NIPD. Fetal sex and fetal RhD status determination by cffDNA analysis is already in clinical use in certain countries. For routine use, this test is limited by the amount of cell-free maternal DNA in blood sample, the lack of universal fetal markers, and appropriate reference materials. To improve the accuracy of detection of fetal specific sequences in maternal plasma, internal positive controls to confirm to presence of fetal DNA should be analyzed. We have developed strategies for noninvasive determination of fetal gender, and fetal RhD genotyping using cffDNA in maternal plasma, using real-time quantitative polymerase chain reaction (RT-PCR) including RASSF1A epigenetic fetal DNA marker (gender-independent) as internal positive controls, which is to be first successful study of this kind in Korea. In our study, accurate detection of fetal gender through gestational age, and fetal RhD genotyping in RhD-negative pregnant women was achieved. In this assay, we show that the assay is sensitive, easy, fast, and reliable. These developments improve the reliability of the applications of circulating fetal DNA when used in clinical practice to manage sex-linked disorders (e.g., hemophilia, Duchenne muscular dystrophy), congenital adrenal hyperplasia (CAH), RhD incompatibility, and the other noninvasive pregnant diagnostic tests on the coming soon. The study was the first successful case in Korea using cffDNA in maternal plasma, which has created a new avenue for clinical applications of NIPD.
convenient method for NIPD has long been sought to reduce this risk of miscarriage and allow earlier testing.
To stratify pregnant women according to their risk of carrying a fetus affected by chromosomal aneuploidy, several screening methods have been developed, including ultrasonography and maternal serum biochemistry 1) . These methods, however, are targeted at epiphenomena associated with the chromosomal aneuploidies, and have limited sensitivities and specificities, with strictly defined gestational age windows that must be used for specific tests. To circumvent such limitations, there is a need for the development of a new generation of noninvasive tests that target the core pathology of a fetus.
From the 1960s to 1990s, many researchers have investigated a variety of approaches for the isolation of fetal nucleated cells from maternal blood [2] [3] [4] . The rarity of circulating fetal nucleated cells in maternal blood has limited the practicality of these approaches and their diagnostic sensitivity, specificity and reproducibility.
The large-scale NIH-funded National Institutes of Health Fetal Cell Study (NIFTY) showed that the enrichment and analysis of circulating fetal cells was not suitable for clinical application 5) . It was clear from these figures that an alternative approach for the direct detection of fetal genetic material from maternal blood, rather than through the isolation of fetal nucleated cells in maternal blood, was needed.
Between the 1970s and 1990s, a parallel group of investigators was studying the intriguing phenomenon of cell-free DNA in the plasma of human subjects. One particularly interesting line of research was the detection of tumor-derived DNA in the plasma of women suffering from a variety of cancers 6, 7) . Inspired by such work, Lo et al. hypothesized in 1997 1) that a fetus might also release its DNA in cell-free form into the plasma of its mother. This hypothesis has led to the direct experimental demonstration of cell-free male fetal DNA in the blood of women carrying male fetuses. This discovery has opened up new possibilities for NIPD.
Cell-free fetal DNA (cffDNA) originates from apoptotic placenta cells (trophoblasts) derived from the embryo 8, 9) and comprises around 3-6% of the total cell-free DNA in maternal circulation from the first trimester onwards,
with concentrations that increase with gestational age 10) . In contrast to fetal cells 11) , cffDNA clears very rapidly from the maternal plasma within hours after delivery 12) .
Development of the technology required for safe and effective NIPD required the concerted effort of many different experts with access to clinical practice. The
Special Noninvasive Advances in Fetal and Neonatal
Evaluation Network (SAFE) provides these facilities 13) .
SAFE was fundamental in the implementation of NIPD for fetal gender determination in parts of Europe, and has facilitated implementation of fetal RhD typing, by developing the standards required when using these new technologies in clinical practice 14) . The objective of this study is to provide an introduction to new technologies involving maternal plasma cffDNA for NIPD and to set up its clinical applications in Korea.
1. Detection of cell-free fetal DNA
1) The detection of Y-related sequences in cell-free fetal DNA
Isolating cffDNA in an overwhelming background of maternal cell-free DNA is a significant technical challenge. During early and late pregnancy, fetal DNA constitutes a mean of approximately 3-6% of total cellfree DNA in maternal plasma 10) , with the obvious implication that most of the DNA in the plasma is maternal in origin. There are many general problems associated with detecting cffDNA in maternal circulation: 1) the concentration of all cell-free DNA in blood is relatively low; 2) the total amount of cell-free DNA varies between individuals; 3) the fetus inherits half its genome from the mother.
A number of methods have been developed to address these problems. Initially, the cell-free DNA must be separated from the rest of the blood. Once a sample of maternal blood has been taken, the plasma fraction is separated from cellular matter by centrifugation. Previous studies have revealed that the way plasma is derived from maternal whole blood has important implications for the analysis of maternal plasma DNA 15) . To ensure consistent and reliable analytical results, cellular elements should be eliminated from maternal plasma either by adopting a two-step centrifugation protocol or filtration of plasma 16, 17) . Contamination of plasma with residual cellular elements could result in a fluctuant background of maternal DNA, affecting the quantitative interpretation of maternal plasma total DNA concentration 16) .
Fetal DNA was detectable in maternal plasma and serum 1, 10, 18) . For most laboratories, plasma has become the material of choice for NIPD because it contains less maternal DNA, which is presumably released from maternal white blood cells during the clotting process.
The concentration of maternal DNA derived from plasma remains stable for 6 hours 19) . These data further support the advantage of maternal plasma over serum for fetal DNA analysis and suggest that maternal blood samples collected into EDTA tubes should be processed within 6 hours.
Once the cell-free DNA fragments have been purified, small differences between the fetal and maternal DNA sequences are exploited to make a specific fetal diagnosis. . Many groups perform replicate or triplicate analyses, and it was reported that analytical results can be interpreted with greater confidence when higher number of replicates are performed 24) . A thoroughly optimized protocol for the extraction of DNA from maternal plasma and further standardization of the RT-PCR protocol, defining the optimal number of replicates per sample, are still needed.
2) Polymorphic marker analysis in both maternal and cell-free fetal DNA genomes, but may not be directly linked to a specific disease. Although there are many studies confirming that this method of detection is possible [25] [26] [27] , it relies on selective enrichment of the cffDNA followed by analysis by a highly sensitive technique such as mass spectrometry, as the maternal and fetal genotypes in question only differ by a single base-pair making them challenging to distinguish. It also relies on finding SNPs that differ between the maternal and paternal genomes. .
3) Universal fetal DNA markers (fetal epigenetic markers)
The limitations of the two approaches above have led to the search for a specific fetal marker that could be used universally in NIPD. Such candidates include loci that are subjected to differential epigenetic modification in the mother and fetus. Recent work has revealed that the promoter region of two tumor suppressor genes-maspin 29) and RASSF1A . However, the preferential detection of unmethylated fetal sequence is more tedious and less sensitive than the detection of methylated material 29) .
Fortunately, in the RASFF1A promoter, it is the fetal DNA that is preferentially hypermethylated and ma- .
The use of hypermethylated RASSF1A sequences as the universal fetal marker is limited only for women with no prior malignancies in medical history as the hypermethylated RASSF1A sequence can originate from residual cancer cells rather than from fetal part of placenta and can be fetal non-specific. .
Clinical applications of noninvasive prenatal diagnosis
There . Fig. 4 . Hypermethylated RASSF1A test system to confirm the presence of cffDNA in SRY-negative samples testing; multiplex RT-PCR for the RASSF1A promoter gene using FAM-labeled probes and using DNA both undigested and digested with BstU1 49) . The beta-actin gene was used as an internal control to show that enzyme digestion was complete. The analysis data show the signals crossing the threshold for these samples: undigested control DNA from a non-pregnant female. Note that after digestion, the signal does not cross the threshold. Undigested patient DNA -this signal represents amplification of RASSF1A from plasma-derived cffDNA and maternal DNA. Digested patient DNA -this signal above threshold remaining after BstU1 digestion shows the cffDNA is present, as the fetal gene is hypermethylated and enzyme-resistant; samples typing SRY-negative are predictive of a female fetus.
dystrophy, Hunter's disease, and adrenoleukodystrophy, which confer significant morbidity or mortality, require genetic prenatal diagnosis only when the fetus is male.
Diagnostic testing for many of these conditions is available by molecular testing of chorionic villi obtained following CVS, which can be performed from around 11 weeks gestation.
Early fetal gender determination using cffDNA could reduce the number of invasive diagnoses required for each specific disease by half, with the particular advantage of sparing most female fetuses from unnecessary invasive diagnostic testing 31) (Fig. 2) . In a recent British national audit of fetal gender determination performed using cffDNA in women requesting prenatal genetic testing for X-linked disorders, there was a 45% reduction in invasive testing, with the most women carrying female fetuses opting not to undergo CVS 1, 32) . Noninvasive fetal gender determination by ultrasound and analysis of cffDNA in maternal plasma also provide a reliable way of avoiding invasive testing for carriers of hemophilia 33) ( Table 2 ).
The other major use of NIPD for fetal sex determination is in the management of CAH. CAH is a group of genetic disorders resulting from abnormalities of adrenal steroid production. Most are due to defects in the CYP21A2 gene, which encodes 21-hydroxylase, and result in overproduction of adrenal androgens. The development of male external genitalia is unaffected by the excess androgens, but varying degrees of virilization occur in affected female fetuses after exposure to high levels of androgens 34) . Virilization begins from early as 8 weeks gestation, but maternal administration of dexamethasone, which can cross the placental barrier, suppresses the hypothalamic-pituitary-adrenal (HPA) axis and can reduce or prevent virilization 35) . Despite being advised that starting dexamethasone by 6 weeks' gestation prevents virilization, many women are unwilling to take steroids, both because of the theoretical risk of side effects and because seven out of eight pregnancies that are treated will be unaffected. Women at risk of CAH requesting gender determination before 
Abbreviations: RQ, real-time quantitative; CN, copy number 7 weeks because they wish to avoid dexamethasone treatment can be offered testing with cffDNA, but must be advised of the limitations of accuracy at early gestations, and should be offered retesting after 7 weeks 31) .
Report by Rijnders et al., proposed starting treatment and testing at a gestational age of 5 weeks and performing serial testing up to 11 weeks or until male DNA is detected 36) . In male fetuses, dexamethasone treatment can be stopped, and invasive diagnostic tests are unnecessary. Once the diagnosis of CAH can be made, unaffected female fetuses could also be withdrawn from therapy without CVS (Fig. 3) . Most patients suffering from CAH are compound heterozygotes, having a different mutation on each copy of chromosome 6 37) . In the future, PCR analysis of fetal DNA could be used to establish the molecular diagnosis of CAH, by searching for paternal inherited mutations or deletions in the CYP locus of chromosome 6. Other indications for fetal gender determination using cffDNA include the identification of abnormal genitalia in fetal ultrasound, apparent Abbreviation: M/F, number of male/female-bearing pregnancies analyzed Sensitivity: number of male-bearing pregnancies correctly identified/total of male-bearing pregnancies tested. Specificity: number of femalebearing pregnancies correctly identified/total of female-bearing pregnancies tested. Positive predictive value: number of male-bearing pregnancies correctly identified/total of positive results at RT-PCR. Negative predictive value: number of female-bearing pregnancies correctly identified/total of negative results at RT-PCR. Accuracy: total of male-and female-bearing pregnancies correctly identified/total of pregnancies tested We have incorporated the use of a RASSF1A system and the existing SRY system as internal positive controls for fetal gender determination, which is the first successful study of this kind in Korea (Table 3 , Fig. 4 ). Table 3 . Among them, 20 were SRY-positive and 15 were SRY-negative. The hypermethylated RASSF1A sequences were detectable in all 15 pregnant women with SRY-negative, and they confirmed the fetal gender as female. . Representative amplification curves showing real-time monitoring of fluorescence intensity for PCR RhD exon 7 as a function of the number of cycles. RhD+ control: plasma sample from an RhD-positive woman; RhD-positive fetus: plasma sample from pregnant woman carrying an RhD-positive fetus; RhDcontrol: plasma sample from an RhD-negative man; RhDnegative fetus: plasma sample from a pregnant woman carrying an RhD-negative fetus.
The SRY sequence was detected by RT-PCR in all pregnant women bearing male fetuses. The sensitivity of the determination of male gender from maternal plasma was 100%, the specificity was 100%, and the accuracy was 100% (Table 4) .
Quantitative fetal DNA data from the maternal plasma relationship with gestational age is summarized in Table   5 . These data show that the concentrations of fetal DNA in plasma are higher in late gestation than in early ges- In clinical audits in Europe, fetal gender determination using cffDNA can be performed efficiently in samples taken after 7 weeks of gestation using stringent reporting criteria. Parents should be advised of the small risk of discordant results and of the possibility that repeat testing may be required to resolve inconclusive results.
Ultrasound should be used to confirm the gestation and check for twins before taking maternal blood and should also be offered to confirm the fetal gender reported using cffDNA 38) .
2) Fetal RhD determination (Fetal RhD genotyping)
Hemolytic diseases of fetuses and newborns (HDFN) still contribute to perinatal morbidity and mortality, in spite of widespread immnoprophylaxis 39, 40) . Currently, 41) when it was extensively developed and widely applied. The majority of NIPD studies of Rhesus factor using cffDNA was a RT-PCR 42) to identify the presence of the RhD gene in RhD-negative mothers. Many laboratories prefer to include an amplification of exon 7, which appears to provide a higher affinity reaction than exon 10 43, 44) . In the UK, determination of fetal RhD status is now accepted for management of high-risk, sensitized pregnancies, and fetal gender determination is also becoming increasingly commonplace in specialist centers for pregnancies at risk of specific inherited disease.
There are multiple reports of high degrees of accuracy for the NIPD of the fetal D status in RhD-negative mothers (Table 6) 45)
, and this was introduced as a routine service by several European centers 25, 46, 47) . 48) .
In our study, we analyzed a total of 44 maternal plasma . Fig. 8 . Hypermethylated RASSF1A test system to confirm presence of cell cffDNA in samples testing as RhD-and SRY-negative; multiplex RT-PCR for the RASSF1A promoter gene using FAM-and VIC-labeled probes and using DNA both undigested and digested with BstU1 49) . The beta-actin gene was used as an internal control to show that enzyme digestion was complete. The analysis data show the signals crossing the threshold for undigested control DNA from a non-pregnant female. Note that after digestion, the signal does not cross the threshold. Undigested patient DNA -this signal represents amplification of RASSF1A from plasmaderived cffDNA and maternal DNA. Digested patient DNA -this signal above threshold remaining after BstU1 digestion shows the cffDNA is present, as the fetal gene is hypermethylated and enzyme-resistant; samples typing RhD-and SRYnegative are predictive of a female RhD-negative fetus. We have concurrently incorporated the use of the RASSF1A system and the existing SRY system as internal positive controls for fetal RhD genotyping, making this the first study of this kind in Korea (Fig. 7, 8 ). The fetal RhD-negative genotype is interpreted as RhD negative when a maternal plasma sample negative for RhD is shown to be positive for hypermethylated RASSF1A.
The study showed that false-negative diagnosis was avoided in samples that were negative for both RhD and RASFF1A sequences. The failure to detect hypermethylated RASSF1A sequences signified the lack of fetal DNA in the maternal plasma sample. The fetal RhD genotyping result could not be interpreted (Fig. 7) . We confirmed the fetal DNA in all samples from pregnant women including RhD-negative female fetuses.
In this study, we show that the assay is sensitive, easy, and reliable. It is the best method for assessing RhD fetal status in RhD-negative mothers and is the first 
